Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis.

Oncol Lett · 2022 · PMC9494298 · PMID 36238837

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Although there may be significant bias in assessing outcome indicators due to patient enrollment differences, the results suggest that the HAIC-oxaliplatin plus sorafenib combination should be more widely used.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.